{"id":"NCT05501860","sponsor":"American Genomics, LLC","briefTitle":"A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution","officialTitle":"A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaine Sterile Topical Ophthalmic Solution","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-30","primaryCompletion":"2022-12-07","completion":"2022-12-07","firstPosted":"2022-08-16","resultsPosted":"2024-10-09","lastUpdate":"2024-10-09"},"enrollment":249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Anesthesia, Local"],"interventions":[{"type":"DRUG","name":"AG-920","otherNames":["articaine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AG-920","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"From Day 1 (treatment day) to 4 days following treatment day; 90 days following treatment for subjects participating in specular microscopy.","effectByArm":[{"arm":"AG-920","deltaMin":40,"sd":null},{"arm":"Placebo","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":166},"commonTop":["Instillation site pain"]}}